News
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
14d
Axios on MSNVinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Wellbeing Whisper on MSN1d
Why Most Americans Won't Need Covid Boosters Anymore and What It Means for YouWe want to know more about what these products are doing,” said Dr. Vinay Prasad during a recent FDA livestreamed ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
16d
Scripps News on MSNDrug industry critic Vinay Prasad will lead FDA's vaccine oversightVinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and gene therapy regulation.
For a brief period in 2022, Dr. Vinay Prasad faked a concern about routine vaccines to infect unvaccinated children with ...
If there’s anything that Dr. Vinay Prasad, the controversial new appointee to lead the Center for Biologics Evaluation and Research, or CBER, a top office at the Food and Drug Administration ...
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
FDA Commissioner Marty Makary, M.D., and Center for Biologics Evaluation and Research (CBER) head Vinay Prasad, M.D., laid out the agency's “evidence-based approach to COVID-19 vaccination” in ...
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
WASHINGTON — Vinay Prasad, an academic and fierce ... including the Center for Biologics Evaluation and Research, the unit he will now lead. After reports of his appointment, the S&P Biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results